216 related articles for article (PubMed ID: 30744947)
1. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira
Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J
Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.
Lee N; Lee JJ; Yang H; Baek S; Kim S; Kim S; Lee T; Song D; Park G
MAbs; 2019 Jan; 11(1):129-144. PubMed ID: 30296198
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D; Yun J; Hwang SJ; Park SJ
Adv Ther; 2019 Feb; 36(2):442-450. PubMed ID: 30554330
[TBL] [Abstract][Full Text] [Related]
4. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L
MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156
[TBL] [Abstract][Full Text] [Related]
5. Consistency of Product Quality for SB5, an Adalimumab Biosimilar.
Lee JJ; Lee N; Seo YJ; Kim I
BioDrugs; 2023 Mar; 37(2):271-277. PubMed ID: 36719640
[TBL] [Abstract][Full Text] [Related]
6. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.
Kronthaler U; Fritsch C; Hainzl O; Seidl A; da Silva A
Expert Opin Biol Ther; 2018 Aug; 18(8):921-930. PubMed ID: 29962245
[TBL] [Abstract][Full Text] [Related]
7. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
Schreiber S; Yamamoto K; Muniz R; Iwura T
Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
[TBL] [Abstract][Full Text] [Related]
9. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
von Richter O; Lemke L; Haliduola H; Fuhr R; Koernicke T; Schuck E; Velinova M; Skerjanec A; Poetzl J; Jauch-Lembach J
Expert Opin Biol Ther; 2019 Oct; 19(10):1075-1083. PubMed ID: 30698045
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers.
Jamshidi A; Sabzvari A; Anjidani N; Shahpari R; Badri N
Expert Opin Investig Drugs; 2020 Mar; 29(3):327-331. PubMed ID: 31985294
[No Abstract] [Full Text] [Related]
12. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
[TBL] [Abstract][Full Text] [Related]
13. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi
Gisbert JP; Gaffney K; Young D; Ebbers HC; Girolomoni G
Expert Opin Biol Ther; 2022 Feb; 22(2):109-121. PubMed ID: 34918591
[TBL] [Abstract][Full Text] [Related]
14. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab.
Velayudhan J; Chen YF; Rohrbach A; Pastula C; Maher G; Thomas H; Brown R; Born TL
BioDrugs; 2016 Aug; 30(4):339-51. PubMed ID: 27422671
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
Shin D; Lee Y; Jeong D; Ellis-Pegler R
Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
[TBL] [Abstract][Full Text] [Related]
18. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®.
Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S
AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®).
Kwon JC; Kwon OH; Jeong RU; Kim N; Song S; Choi I; Lee J; Horiuchi T
Anim Cells Syst (Seoul); 2021; 25(3):182-194. PubMed ID: 34262661
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis.
Song SH; Woo SJ
Ocul Immunol Inflamm; 2024 Jan; ():1-5. PubMed ID: 38194436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
